Data from microarrays co-developed by OGT to be presented at ECC 2011

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced details of its upcoming workshop at the European Cytogenetics Conference 2011, held in Porto, Portugal (2–5 July).

Professor Joris Vermeesch, Head of the Laboratory for Cytogenetics and Genome Research at Katholieke Universiteit Leuven will present data obtained using aCGH microarrays co-developed with OGT. The presentation entitled “About inherited pathogenic and de novo benign CNVs”, will discuss the use of aCGH to deliver new insights into the association between copy number variation and a range of developmental disorders. Some of the data to be presented was obtained using a unique custom microarray that combines OGT’s CytoSure™ ISCA 8x60k and CytoSure Syndrome Plus v2 2x105k arrays into a 4x180k format. This design facilitates data sharing between ISCA consortium members and the comparison of new data with legacy data. Additional data generated using this array was presented at the recent European Society of Human Genetics (ESHG) Meeting in Amsterdam by Paul Brady, a PhD student in Professor Vermeesch’s lab. This presentation entitled “The use of array CGH for prenatal diagnosis of foetuses with congenital malformations detected by ultrasound” is available to download on the OGT website.

The new combined array is just one tool developed as part of the successful ongoing relationship between OGT and the Katholieke Universiteit Leuven. Researchers at the University have also recently utilised OGT CytoSure custom designed arrays, CytoSure DNA Labelling Kits and class-leading CytoSure Interpret Software to identify genomic imbalances associated with congenital diaphragmatic hernia (CDH), with the work subsequently published in the journal Prenatal Diagnosis. In addition, studies conducted at the University were instrumental in the development of the CytoSure Aneuploidy array, which allows simple, reliable and cost-effective detection of whole chromosomal imbalances in miscarriage samples. Such examples excellently illustrate how the collaborations formed between OGT and world-class academic institutes are leading to the development of superior tools for use in cytogenetic research. Professor Joris Vermeesch commented: “The complex nature of our work requires a high level of accuracy combined with in-built flexibility. Working with OGT provides both, allowing us to optimise our aCGH design and workflow to generate the best results possible from each individual study.”

Register now for OGT’s ECC workshop.

Source: www.ogt.co.uk

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Gene Technology. (2022, December 23). Data from microarrays co-developed by OGT to be presented at ECC 2011. News-Medical. Retrieved on November 14, 2024 from https://www.news-medical.net/news/20110628/Data-from-microarrays-co-developed-by-OGT-to-be-presented-at-ECC-2011.aspx.

  • MLA

    Oxford Gene Technology. "Data from microarrays co-developed by OGT to be presented at ECC 2011". News-Medical. 14 November 2024. <https://www.news-medical.net/news/20110628/Data-from-microarrays-co-developed-by-OGT-to-be-presented-at-ECC-2011.aspx>.

  • Chicago

    Oxford Gene Technology. "Data from microarrays co-developed by OGT to be presented at ECC 2011". News-Medical. https://www.news-medical.net/news/20110628/Data-from-microarrays-co-developed-by-OGT-to-be-presented-at-ECC-2011.aspx. (accessed November 14, 2024).

  • Harvard

    Oxford Gene Technology. 2022. Data from microarrays co-developed by OGT to be presented at ECC 2011. News-Medical, viewed 14 November 2024, https://www.news-medical.net/news/20110628/Data-from-microarrays-co-developed-by-OGT-to-be-presented-at-ECC-2011.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
OGT increases NGS cancer panel content to provide more flexibility for customization